⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065889 | 1.00 | — | — | |
| SCHEMBL13558432 | 1.00 | — | — | |
| SCHEMBL2358820 | 0.93 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL24221676 | 0.91 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL11024494 | 0.91 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL18207814 | 0.91 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL3832305 | 0.85 | — | — | |
| SCHEMBL13344 | 0.84 | HTR6 (0.38) | — | |
| Ammonia Solution, Strong SCHEMBL2950437 | 0.83 | — | — | |
| SCHEMBL21779378 | 0.83 | SMN1; SMN2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| EP-4642778-A1 | LSD1 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024240213-A1 | FUSED TRICYCLIC SUBSTITUTED ISOXAZOLIDINYL UREA DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-11-28 | — | — | WO | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2012121863-A1 | (--)- HUPERZINE A PROCESSES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | YALE UNIVERSITY (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | disclosed |
| US-7910730-B2 | Process for the preparation of delmopinol and derivatives thereof | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2011-03-22 | — | — | US | disclosed |
| US-20100222579-A1 | Process for the Preparation of Delmopinol and Derivatives Thereof | ARTUS SURROCA JUAN JOSE | 2010-09-02 | — | — | US | disclosed |
| EP-1486501-B1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-7250429-B2 | Aminomethyl-substituted thiazolobenzimidazole compounds | ASTELLAS PHARMA INC. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148642-A1 | Aminomethyl-substituted thiazolobenzimidazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1486501-A1 | AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| EP-0783305-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0783305-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |